Genitourinary Cancers

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

Rolling submission of a new drug application for cabozantinib has been initiated for patients with advanced renal cell carcinoma who have received one prior therapy.

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

Robert Figlin, MD, discusses the evolution of TKIs in renal cell carcinoma, the novel agents and changes to established therapies he is most excited about, and the challenges that still remain.

Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.

The challenge of pelvic failure following contemporary cystectomy has been engaged and the clinical trials to pursue the amelioration of this problem have commenced.

Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses treatment challenges for patients with refractory, metastatic urothelial carcinoma.

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guérin therapy.

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses a phase 1b trial investigating avelumab, an anti-PD-L1 antibody, in patients with refractory, metastatic urothelial carcinomas.

Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.

Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).

Nivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.

Second-line treatment with cabozantinib reduced the risk of progression or death by 42% compared with everolimus in patients with advanced renal cell carcinoma.

Renal cell carcinoma with sarcomatoid differentiation, a histology that is often resistant to targeted therapies and interleukin-2 immunotherapy (IL-2), may respond to anti–PD-1/PD-L1 therapies.

Titrating dose levels of axitinib (Inlyta) improved response rates and extended overall survival by 12.3 months in patients with metastatic renal cell carcinoma.

Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.

Cabozantinib (Cometriq) has received a breakthrough therapy designation from the FDA for the treatment of patients with advanced renal cell carcinoma following one prior therapy.

Dicken Shiu-Chung Ko, MD, Department of Urology, Massachusetts General Hospital, discusses current evidence of renal transplantation following tumor excision.

Results from clinical trials demonstrate that immunotherapy is ready to take center stage in the fight against bladder cancer.

The FDA has granted a breakthrough therapy designation to lenvatinib as a potential treatment for patients with advanced renal cell carcinoma who have received a VEGF-targeted therapy.